Tiziana Life Sciences PLC   | AIM:TILS


KEY POINTS


  1. Data suggests that Bcl-3 may be a master regulator of this metastatic property not only in the more aggressive breast cancers but across the whole clinical spectrum of breast disease.

  2. In silico modelling of the BCL-3 complex & screening simulation has identified potential inhibitors

  3. Leads from in silico screening and their structural analogs were synthesised and found to be potently effective in in vitro assays; and in vivo in a mouse model with a human breast cancer cell line.

 

IP & Research Collaboration Agreement

Tiziana has two agreements in place with Cardiff University:

  1. A research agreement to screen and identify suitable clinical candidates

  2. An exclusive worldwide license to use the IPR and know-how arising out of the Research Agreement, including the Bcl-3 patent, to research, develop, manufacture, market, use and sell products

OVERVIEW


Tiziana Life Sciences has entered into a License Agreement with Cardiff University providing an exclusive worldwide license over Cardiff University’s Bcl-3 patent.

All intellectual property is owned by Cardiff University, which has granted the Company an option to an exclusive licence to any compound with potential therapeutic interest against Bcl-3 arising directly from the research project.  This option has been exercised and Cardiff University procured the licence of the intellectual property from its licensing subsidiary University College Cardiff Consultants Limited (UCCC).

UCCC has granted an exclusive worldwide licence to Tiziana Life Sciences to use the IPR and know-how arising out of the Research Agreement (including the Bcl-3 Patent) to research, develop, manufacture, market, use and sell products.

The invention claimed in the patent relates to:

  1. novel inhibitors of B-cell Lymphoma 3 (Bcl-3);

  2. novel therapeutics or compositions comprising said inhibitors of Bcl-3; and

  3. the use of said therapeutics or compositions to treat cancer and particularly metastatic cancer or secondary cancers.

At this stage, the patent application is very wide and has not been limited to specific cancers or methods of treatment, although specific cancers and methods of treatment are claimed in addition to the broader claims of the patent.